Pramipexole-related chronic lower limb oedema in a patient with Parkinson's disease.

Zavala JA, Munhoz RP, Teive HA.

J Clin Neurosci. 2012 Sep;19(9):1298-9. doi: 10.1016/j.jocn.2011.12.011.

The unrelated communication interlude (UCI)--an automatic behavior phenomenon in Parkinson's disease.

Fusegi K, Hattori N, Mizuno Y, Mori H.

Parkinsonism Relat Disord. 2012 Sep;18(8):986-9. doi: 10.1016/j.parkreldis.2012.05.006.

A patient of Ebstein's anomaly associated with biventricular noncompaction presented with Wolf Parkinson White syndrome - A rare presentation.

Patra S, Singla V, Kharge J, Ravindranath KS, Manjunath CN.

J Cardiovasc Dis Res. 2012 Oct;3(4):323-5. doi: 10.4103/0975-3583.102721.

Brain transcriptomic profiling in idiopathic and LRRK2-associated Parkinson's disease.

Botta-Orfila T, Sànchez-Pla A, Fernández M, Carmona F, Ezquerra M, Tolosa E.

Brain Res. 2012 Jul 23;1466:152-7. doi: 10.1016/j.brainres.2012.05.036.

Vocal responses to perturbations in voice auditory feedback in individuals with Parkinson's disease.

Liu H, Wang EQ, Metman LV, Larson CR.

PLoS One. 2012;7(3):e33629. doi: 10.1371/journal.pone.0033629.

Prospective study of statin use and risk of Parkinson disease.

Gao X, Simon KC, Schwarzschild MA, Ascherio A.

Arch Neurol. 2012 Mar;69(3):380-4. doi: 10.1001/archneurol.2011.1060.

Case-control study of blink rate in Parkinson's disease under different conditions.

Fitzpatrick E, Hohl N, Silburn P, O'Gorman C, Broadley SA.

J Neurol. 2012 Apr;259(4):739-44. doi: 10.1007/s00415-011-6261-0.

Non-gaussianity of low frequency heart rate variability and sympathetic activation: lack of increases in multiple system atrophy and Parkinson disease.

Kiyono K, Hayano J, Kwak S, Watanabe E, Yamamoto Y.

Front Physiol. 2012 Feb 22;3:34. doi: 10.3389/fphys.2012.00034.

Motor features and response to oral levodopa in patients with Parkinson's disease under continuous dopaminergic infusion or deep brain stimulation.

Elia AE, Dollenz C, Soliveri P, Albanese A.

Eur J Neurol. 2012 Jan;19(1):76-83. doi: 10.1111/j.1468-1331.2011.03437.x.

Comparison of enrollees and decliners of Parkinson disease sham surgery trials.

Kim SY, Wilson RM, Kim HM, Holloway RG, De Vries RG, Frank SA, Kieburtz K.

Mov Disord. 2012 Apr;27(4):506-11. doi: 10.1002/mds.24940.

Anchanling reduces pathology in a lactacystin- induced Parkinson's disease model.

Li Y, Wu Z, Gao X, Zhu Q, Jin Y, Wu A, Huang AC.

Neural Regen Res. 2012 Jan 25;7(3):165-70. doi: 10.3969/j.issn.1673-5374.2012.03.001.

Dopaminergic neurons for Parkinson's therapy.

Lindvall O.

Nat Biotechnol. 2012 Jan 9;30(1):56-8. doi: 10.1038/nbt.2077. No abstract available.

Tricyclic antidepressants delay the need for dopaminergic therapy in early Parkinson's disease.

Paumier KL, Siderowf AD, Auinger P, Oakes D, Madhavan L, Espay AJ, Revilla FJ, Collier TJ; Parkinson Study Group Genetics Epidemiology Working Group..

Mov Disord. 2012 Jun;27(7):880-7. doi: 10.1002/mds.24978.

Iowa Gambling Task in patients with early-onset Parkinson's disease: strategy analysis.

Gescheidt T, Czekóová K, Urbánek T, Mareček R, Mikl M, Kubíková R, Telecká S, Andrlová H, Husárová I, Bareš M.

Neurol Sci. 2012 Dec;33(6):1329-35. doi: 10.1007/s10072-012-1086-x.

Genetic Screening of the Mitochondrial Rho GTPases MIRO1 and MIRO2 in Parkinson's Disease.

Anvret A, Ran C, Westerlund M, Sydow O, Willows T, Olson L, Galter D, Belin AC.

Open Neurol J. 2012;6:1-5. doi: 10.2174/1874205X01206010001.